Retinal changes: a mortality risk in non-diabetics

Article

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

A study published in the September issue of the American Journal of Epidemiology, suggests that retinal changes have possible prognostic implications regarding the survival of persons with diabetes.

Despite retinopathy being fairly common among non-diabetics, its prognostic implications are not fully understood. Ronald Klein and colleagues from the University of Wisconsin, USA and the Federal University of Sao Paulo, Brazil hypothesized that retinal alterations are associated with increased mortality. In order to investigate this, they evaluated survival rates among 4,292 non-diabetic participants (age range, 43-84 years) of the Beaver Dam Eye Study.

Retinal photographs were used to classify retinopathy into four groups: no retinopathy, retinal haemorrhage only, retinal micro-aneurysm or moderate or worse retinopathy. Survival was analyzed over a 14-year follow-up period in five-year intervals.

The baseline prevalence of retinopathy was 7.6%. After the 14-year follow-up period it was discovered that moderate retinopathy, at baseline, increased the risk of all-cause mortality by 24% and ischaemic heart disease by more than three-fold.

Based on these results, the researchers believe that retinal changes do have possible prognostic implications regarding the survival of persons without diabetes.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.